Rokuro Masuma and Satoshi Omura* The Kitasato Institute, Tokyo 108, Japan (Received for publication July 19, 1999) In clinical practice the antibiotic lincomycin (Lincocin ) has been replaced by its chemically modified analogues 7-(*S)-chloro-7-deoxylincomycm (clindamycin, Klimicin®, Dalacin®) and its 2-O-phosphate and palmitoyl ester derivatives.
These new antibiotic analogues are active against Gram-positive and -negative anaerobic microorganisms, possess high concentration in the tissues, and readily penetrate into the bones. These results suggest that further modification of the structure of the parent antibiotic, lincomycin, may be associated with additional, advantageous pharmacological effects. Recently wehave described our studies concerning the removal1} of the acyl side-chain, its replacement^and the oxidation of the sulfur atom3) of lincomycin. The antibacterial activity of one of the prepared compounds, 7-(^)-azido-7-deoxylincomycin (2) was found to be higher than that of lincomycin, but was lower than that of clindamycin4).
The present paper reports on further chemical modification of compound 2. For the transformation of the azido group by the Staudinger reaction^offers a promising possibility.
Thus, 2 was first converted into the corresponding phosphinimine by treatment with triphenylphosphine, which further reacted with heterocyclic secondary amines (A^methyl-piperazine and morpholine) in the presence of carbon dioxide ( Fig. 1) and resulted in the desired substituted C-7-ureido antibiotic derivatives (3 and 4) . The spectral data supporting the proposed structures, and the physico-chemical properties of these compounds are shown in Tables 1 and 2 . and (E) 7 : 3 CHC13-MeOH.Evaporations were carried out under diminished pressure (bath temperature below 40°C).
Each of the synthesized compoundspossessed appropriate microanalytical data.
7-(A^-Methylpiperazinyl-ureido)-7 -deoxylincomycin (3 ) Compound 2 (0.2 mmol) and 7V-methylpiperazine (0.2 mmol) were dissolved in dry tetrahydrofuran (2 ml) and the solution was saturated with carbon dioxide. A solution of triphenylphosphine (0.2mmol) in dry tetrahydrofuran (2 ml) was added dropwise to the reaction mixture, which was then stirred at room temperature for 20 hours. Following evaporation, the residue was submitted to column chromatography (A) to obtain 76.4% of pure 3.
7-(i?)-Amino-7-deoxylincomycin (6) 7 -(Morpholmoyl-ureido)-7-deoxylincomycin (4) The reaction of 2 with morpholine was carried out (with 17 hours reaction time) as described above for the preparation of3 to furnish 71%of pure 4.
7-Azido-7-deoxy-peracetyllmcomycm
To an ice-cold solution of 2 (0.15 mmol) in dry pyridine (1 ml) acetic anhydride (1 ml) was added dropwise, the reaction mixture was allowed to stand at roomtemperature for 24 hours, and poured onto ice-water. The mixture was extracted with chloroform (2X5 ml), the organic layer was washed with dilute acetic acid, water, and saturated aq. A solution of 5 (0.55mmol) and triphenylphosphine (0.55mmol) in dry ether (3ml) was kept at room temperature for 20 hours. The solvent was distilled off under diminished pressure, and the residue was triturated with hexane to obtain 94.3% of a crystalline residue, m.p.
103~106°C. This was <9-decetylated under the Zemplen conditions,6^and the residue, obtained after usual work-up, was purified by column chromatography (gradient elution D->E) to furnish pure crystalline 6 after trituration with ether.
7-Diethylamino-7-deoxylincomycin (7)
To a mixture of 6 (0.1mmol) and acetaldehyde (0.15 mmol) in dry tetrahydrofuran sodium cyanoborohydride (0.llmmol) was added and the mixture was strirred at room temperature for 1.5 hours. It was then concentrated under diminished pressure and the residue was purified by means of column chromatography (D) to obtain the pure title compound7.
